8/1/2016 | PP | Vical could raise about $7.8 million via private placement of stock
|
4/15/2014 | PP | Vical targets $25 million from at-the-market common stock offering
|
11/7/2012 | PP | Vical secures $50 million through at-the-market common stock offering
|
5/4/2012 | CVHYPF | Vical files $150 million shelf covering stock, debt and preferreds
|
1/6/2012 | PP | Vical to sell $50 million of its common stock through public offering
|
1/5/2012 | PP | Vical plans to price public offering of common stock with greenshoe
|
1/22/2010 | CVHY | Vical files $100 million shelf covering stock, debt and preferreds
|
1/8/2010 | PP | New Issue: Vical seals $25 million equity line of credit with Azimuth Opportunity
|
7/28/2009 | PP | New Issue: Vical announces $10 million registered direct offering of common shares
|
7/28/2009 | PP | Market Commentary: Smithtown secures $14 million; NWM gets funds for drill program; Creston Moly wraps unit sale
|
5/26/2009 | PP | New Issue: Vical increases direct offering of stock-and-warrant units to $20.04 million
|
5/26/2009 | PP | Market Commentary: Vical increases direct offering; Amarin inks deal; Forest Gate to sell units; Jackgreen settles
|
5/22/2009 | PP | New Issue: Vical investors commit $15.4 million via registered direct offering
|
5/22/2009 | PP | Market Commentary: Vical to issue units; PURE Bioscience plans $3 million stock sale; Altair to raise $15 million
|
5/8/2009 | CVIG | Vical files $80 million shelf registration covering stock, debt, units
|
11/24/2008 | SS | James Singer reports stake of 5% in Vical
|
4/23/2007 | SS | Market Commentary: MedImmune deal rekindles buzz of biotech buyouts; Genesco gains; Vonage eyed
|
1/12/2007 | CV | Vical files for $80 million common, preferred stock shelf
|
11/2/2006 | BT | Vical third-quarter revenues down, results consistent with guidance
|
10/20/2006 | BT | Market Commentary: BioVex IPO pulled; Ariad dives; Encysive off; Vical spikes 10%; Amgen higher ahead of results
|
10/20/2006 | PP | Market Commentary: Lev stock climbs on $21 million stock offering; Encysive seals $75 million equity line
|
10/19/2006 | BT | Market Commentary: Asthmatx on deck; Ariad slides after-hours; Siga slips on PIPE; Accentia rises 42% on trial data
|
10/19/2006 | PP | Market Commentary: Vical wraps up another direct stock offering; Siga secures $9.08 million from PIPE
|
10/19/2006 | BTPP | New Issue: Vical secures $25.1 million from direct placement of stock
|
10/17/2006 | PP | Market Commentary: Loral Space, Lear head up PIPE action with two substantial deals; Patron raises $10 million
|
10/16/2006 | BT | Market Commentary: Vical up on PIPE; Amgen sinks on FDA delay; Critical up 16%; Omrix off 14.5% on profit taking
|
10/16/2006 | PP | Market Commentary: Vical settles $12.55 million direct stock sale; Watch Resources plans C$18 million PIPE
|
10/16/2006 | BTPP | New Issue: Vical secures $12.55 million from direct placement of shares
|
9/25/2006 | BT | Vical to start phase 3 melanoma trial with Allovectin-7
|
9/19/2006 | BT | Vical grants additional academic licenses for core technology
|
9/13/2006 | BT | Vical extends patent coverage for Vaxfectin adjuvant
|
8/28/2006 | BT | Market Commentary: Discovery Partners up 9% on MedImmune, Infinity pact; EPIX plunges; Sinovac soars; PDL up
|
8/25/2006 | BT | Vical gets $10 million loan from Oxford Finance
|
8/22/2006 | BT | Market Commentary: Protalix gets $15 million investment as part of merger; Theravance sees positive telavancin trial results
|
8/22/2006 | BT | Vical starts phase 1 study of prime-boost vaccine for HIV
|
8/11/2006 | PP | Market Commentary: Duquesne Light wraps $141.38 million stock sale; Peat Resource prices C$3.5 million PIPE
|
8/10/2006 | PP | Market Commentary: Cytori Therapeutics secures $16.78 million from PIPE; Vical closes $10.01 million stock deal
|
8/10/2006 | BTPP | New Issue: Vical concludes $9.78 million direct placement of stock
|
8/10/2006 | BT | Market Commentary: ImClone slammed after it ditches deal search; Oscient rises 12.5%; Vical sinks
|
8/1/2006 | BT | Vical reports second-quarter revenues up to $7.3 million
|
7/31/2006 | BT | Market Commentary: ImClone off 4%, Repligen soars; Viragen slides, Napo debuts up; Pozen gains; Novavax up 12.5%
|
7/27/2006 | BT | Market Commentary: Adams hit 4%; Conor slips after follow-on; Diomed pockets $10 million from PIPE; Oscient gains
|
7/26/2006 | BT | Market Commentary: DOV comes off highs; Neurocrine extends losses after hours; bird flu stocks fly; NicOx rises
|
6/7/2006 | BT | Vical highlights DNA vaccine technology at medical meeting
|
6/7/2006 | BT | Vical awarded $2.6 million grant to study avian flu vaccine
|
6/1/2006 | BT | Vical's West Nile virus DNA vaccine produces neutralizing antibodies in phase 1 trial
|
5/31/2006 | PP | Market Commentary: Italy's Gentium secures $22.13 million from PIPE; Isonics raises $16 million from convertibles
|
5/30/2006 | BTPP | New Issue: Vical raises $6.9 million in first closing of $10.85 million placement with AnGes MG
|
5/30/2006 | BT | Market Commentary: Cubist new convertible emerges; Vical zooms; Isis climbs; ISTA off despite news; CollaGenex climbs
|
5/30/2006 | BT | Vical to collaborate with AnGes MG on cancer therapeutic Allovectin-7
|
5/30/2006 | PP | Market Commentary: Isis seals $75 million equity line; Vical wraps first tranche of stock deal as part of R&D agreement
|
5/10/2006 | BT | Market Commentary: Alnylam gains as bird flu names slip; AVI pushes vaccine names lower; Novacea ends flat on debut
|
5/2/2006 | BT | Market Commentary: Vical top pick in bird flu flock; Noven sinks on profit taking; NitroMed dives, Myriad higher
|
5/2/2006 | BT | Vical's DNA vaccine protects against avian flu in animal studies
|
3/31/2006 | BT | Vical's DNA vaccine with Vaxfectin shows strong protection against flu, study says
|
3/13/2006 | BT | Vical licensee sanofi-aventis to launch phase 3 angiogenesis study for critical limb ischemia
|
2/21/2006 | BT | Vical's Ebola DNA vaccine shown to be well tolerated, produces immune responses in phase 1 trial
|
2/1/2006 | BT | Vical opens phase 2 trial of DNA vaccine against cytomegalovirus
|
1/27/2006 | BT | Vical files for $70 million common, preferred stock shelf
|
1/24/2006 | BT | Vical licenses core technology to Stanford, Harvard and Yale
|
12/1/2005 | BT | Market Commentary: Rigel Pharma tromped; Oxigene, Biopure launch follow-on deals; Lexicon, LabCorp, Quigley higher
|
11/8/2005 | BT | Market Commentary: Pharmaxis off on stock dilution; Patheon refinancing bank paper; Serono up on sale news
|
11/8/2005 | BT | Vical gets $1 million payment as Merck advances cancer vaccine to phase I trial
|
10/14/2005 | PP | Market Commentary: PNM Resources completes $100 million; Tercica gets $75 million equity line from Kingsbridge
|
10/13/2005 | PP | Market Commentary: FTS Wireless eyes $5 million PIPE; Nstein prices C$5 million stock deal
|
10/12/2005 | BT | Market Commentary: Vical falls 20% on PIPEs deal; Threshold, Dynavax off on stock sales; Pharma Product higher
|
10/12/2005 | PP | Market Commentary: Vical's stock plummets after $22.56 million direct offering; more biotech PIPEs seen possible
|
10/12/2005 | BTPP | New Issue: Vical prices $22.56 million direct placement of stock
|
10/10/2005 | BT | Market Commentary: Holiday makes for thin market; Gilead, niche flu drug names go higher; Human Genome lower yet
|
10/7/2005 | BT | Market Commentary: CoTherix off on follow-on deal; Human Genome slide unabated; Cytogen higher; flu names soar
|